Amidst a backdrop of political tension, the Food and Drug Administration (FDA) has sanctioned a new generic version of mifepristone, a widely used abortion pill. This approval, while a standard regulatory matter, has sparked significant backlash from certain anti-abortion circles.
Evita Solutions, the pharmaceutical company behind the new generic, announced that the FDA has endorsed its affordable version of mifepristone, which is effective for terminating pregnancies up to 10 weeks. The decision was swiftly criticized by Students for Life Action, which described the approval as “a stain on the Trump presidency and another sign that the deep state at the FDA must go.”
Senator Josh Hawley of Missouri also expressed his discontent on social media platform X, stating, “I have lost confidence in the leadership at FDA.”
An FDA spokesperson clarified that the agency has “very limited discretion in deciding whether to approve a generic drug,” emphasizing that FDA officials do not “endorse any product.”
This criticism arises as President Donald Trump’s administration, particularly Health Secretary Robert F. Kennedy Jr., faces mounting pressure from abortion opposition to reexamine mifepristone. The drug, initially approved 25 years ago, has consistently been affirmed as safe and effective by FDA scientists.
In correspondence addressed to Republican attorneys general, both Kennedy and FDA Commissioner Dr. Marty Makary committed to a comprehensive review of the drug’s safety. The FDA, under Makary and Kennedy’s leadership, has previously postponed decisions on vaccines, narrowing approval terms for COVID-19 vaccines, which marks a shift from the agency’s usual scientist-led decision-making process.
The FDA’s original approval of mifepristone dates back to 2000, with access gradually broadened, including the 2019 approval of a generic from GenBioPro. Under President Joe Biden in 2021, the FDA allowed online prescriptions and mail-order delivery, significantly easing access. However, this change has faced persistent opposition.
Approving generic drugs typically follows a routine process at the FDA, with multiple versions often cleared post-patent expiration. Generic manufacturers must demonstrate that their product matches the original’s ingredients and formulation. “This is exactly how our system is supposed to work, and it has worked this way for decades,” noted Mini Timmaraju of Reproductive Freedom for All, asserting that FDA professionals executed their responsibilities appropriately.
While the FDA usually processes such applications within 10 months, Evita Solutions had filed its application four years prior, as per documents on the FDA’s website. On its platform, Evita expresses its commitment to making “safe, affordable, high-quality, effective, and compassionate abortion care” accessible to all.
Evita plans to launch the drug in January. The availability of a second generic is unlikely to impact access to the pill, which is often paired with misoprostol — a combination responsible for about two-thirds of U.S. abortions. Mifepristone facilitates cervical dilation and hormone blockage, while misoprostol induces uterine contractions.
Despite state laws that restrict or ban medication abortions, including mifepristone, ongoing lawsuits challenge these regulations. Major medical organizations, such as the American Medical Association, do not support restrictions on the pill.
This article was originally written by www.npr.org
